 MASON, Ohio--BUSINESS WIRE--AtriCure, Inc. Nasdaq: ATRC, a leading innovator in treatments for atrial fibrillation Afib and left atrial appendage LAA management, announced preliminary financial results for the fourth quarter and full year 2020. We are pleased with our fourth quarter and full-year results which reflect the resiliency and strength of our team, as well as the overarching unmet need in our core markets. COVID-19 continues to impact our revenue as procedure volumes remain b 